Every 10-Q that Galecto, Inc. (GLTO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLTO filings page.
Damora Therapeutics, Inc. reported a larger net loss as it ramps up development of its mutCALR-targeted pipeline and strengthens its balance sheet. For the quarter ended March 31, 2026, net loss was $27.8 million versus $2.5 million a year earlier, driven mainly by a jump in research and development spending.
Research and development expenses rose to $23.8 million, including $17.0 million related to Paragon under the Paragon Option Agreement and $5.0 million of stock-based compensation from the Paramora warrant obligation. General and administrative costs increased to $7.0 million as the company scales its public-company and infrastructure footprint.
Damora ended the quarter with $532.9 million in cash and cash equivalents, boosted by a February 2026 underwritten offering that raised approximately $295.5 million net, and an accumulated deficit of $515.1 million. Management believes current cash resources can fund operations for at least one year. The company is focusing on its mutCALR portfolio (DMR-001, DMR-002, DMR-003) for myeloproliferative neoplasms and has deprioritized further development of GB3226.
Galecto, Inc. (GLTO) filed its Q3 report, highlighting a continued focus on oncology and liver disease programs GB3226 and GB1211 and a tighter cost base. The company reported a net loss of $3.1 million for the quarter and $9.1 million year-to-date. Cash and cash equivalents were $7.6 million as of September 30, 2025, with operating cash use of $7.3 million for the first nine months.
Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to seek additional capital. Operating expenses declined year over year: research and development was $1.4 million in Q3 (driven by CMC and preclinical work), while general and administrative fell to $1.7 million on lower personnel and legal costs.
For GB3226 (dual ENL‑YEATS/FLT3 inhibitor for AML), FDA pre‑IND feedback in September 2025 was consistent with plans to submit an IND in Q1 2026, subject to financing, with an initial Phase 1 design outlined. GB1211 continued in investigator‑initiated combination studies. Shares outstanding were 1,327,212 as of November 3, 2025.